Colorectal Cancer | Topics

Consistent Activity of Trastuzumab Deruxtecan Reported for HER2+ mCRC
June 08, 2021

In line with responses seen at the primary analysis, final results of a phase 2 trial support activity of trastuzumab deruxtecan in HER2-positive metastatic CRC.

Maintenance Therapy Panitumumab Plus 5-FU/Leucovorin Improves Survival in RAS Wild-Type Metastatic CRC
June 08, 2021

Adding panitumumab to 5-FU and leucovorin significantly improved PFS compared with 5-FU/leucovorin alone as a maintenance therapy for patients with RAS wild-type metastatic CRC.

Preferred Treatment of RAS Wild-Type, BRAF V600E Mutant mCRC Favors Bevacizumab Over Cetuximab
June 07, 2021

Certain patients with RAS wild-type colorectal cancer should be treated with bevacizumab in place of cetuximab in combination with FOLFOXIRI.